Mölnlycke
Investor relations
At Mölnlycke, we're driven by a passion for improving healthcare outcomes through innovation and excellence. We are transparent about our strategic objectives, financial performance, and commitment to sustainable growth. We deeply appreciate your interest and trust in Mölnlycke. Your support fuels our mission to make a meaningful impact in healthcare and deliver long-term value to our shareholders.
Mölnlycke key performance stats 2023
-
0 %organic growth
-
0EBIDTA, million EUR
-
0annual sales, million EUR
"Our strong financial position and continued growth allow us to direct our future and continued investments."
Zlatko Rihter Chief Executive Officer
Mölnlycke is owned by Investor AB. Investor AB is listed on NASDAQ QMX Stockholm.
Read moreIn 2024, Mölnlycke has had another strong year, achieving 2,064 MEUR in net sales while improving profitability. This corresponds to a sales growth of 7% compared to 2023, outperforming the market. Financially, the company has improved on the strong performance of last year, with all business areas showing growth.
Furthermore, Mölnlycke continued to enhance its profitability, achieving and EBITDA of EUR 591 million with a corresponding margin of 29%.
Financial information
-
Financial reporting
-
Mölnlycke Annual report
We are transparent about our impact on environment, people and society. Each year, we report on results and performance in the integrated Annual Report.
Mölnlycke integrated Annual Report 2024 covers the year ending on 31 December 2024. The report has been prepared in accordance with Global Reporting Initiative (GRI) standards, in addition to the Taskforce on Climate related Financial Disclosures (TCFD) framework. Additionally, the report has been structured to align with the Corporate Sustainability Reporting Directive (CSRD) format and requirements, though full compliance has not yet been achieved.
-
Investor presentations
-
Capital Markets Day
Capital Markets Day 2023 Presentation
-
Debt maturity
Mölnlycke issues notes on the European bond market under its Euro Medium Term Note (EMTN) programme. Mölnlycke’s has an outstanding debt of EUR 1.800 million which is long-dated and evenly distributed.
In addition to its own liquidity, Mölnlycke has a syndicated multi-currency revolving credit facility of EUR 350 million (unutilized). It was signed in 2023 as a 5+1+1 agreement. Mölnlycke has chosen to execute both the extension options in 2024 and 2025. Final maturity date is April 2030. The facility is backed by a group of seven leading global and regional banks, well diversified to match Mölnlycke’s geographical footprint. The banks are BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB.
-
Credit rating
Mölnlycke and Investor AB are committed to the company’s Investment Grade rating of BBB- (stable) by S&P.
S&P outlook:
Our stable outlook on Mölnlycke reflects our view that the company's leading market position and strong brand portfolio should enable it to sustain positive underlying revenue growth and earnings generation.
-
Board of Directors
Mölnlycke’s Board of Directors has the ultimate responsibility for the company and its operations.
Board of Directors -
Executive Leadership Team
Defines and implements the company’s corporate strategy and ensures day-to-day management of their operations.
Executive Leadership Team -
Our Owner
Investor AB acquired Mölnlycke in 2007. Mölnlycke is the largest wholly-owned subsidiary within Patricia Industries.
Our Owner
Latest news
-
Mölnlycke Health Care inaugurates new global headquarters at GoCo Health Innovation City
Gothenburg, Sweden. 21 May 2025 – Mölnlycke Health Care, a global leader in MedTech, has officially opened its new global headquarters at GoCo Health Innovation City in Gothenburg, Sweden—a major milestone in its journey to drive sustainable healthcare innovation.
-
Mölnlycke Health Care’s long-term target to reach net zero emissions validated by Science Based Targets initiative
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.
-
Mölnlycke Health Care supports the Wound Care Collaborative Community initiative to improve wound dressing standards
Gothenburg, Sweden. May 02, 2025. The Wound Care Collaborative Community (WCCC) is leading a groundbreaking initiative looking to develop a standardised pre-clinical testing framework for wound dressings.
-
Mölnlycke Health Care publishes Annual report for 2024
Gothenburg, Sweden. 1 April 2025. Today Mölnlycke Health Care has published its Annual report for 2024, including the sustainability report.
-
New study demonstrates the potential benefits of dressing regime improvements in delivering value-based chronic wound care
-
Mölnlycke Health Care announces launch of the 2025 Future Summit
Mölnlycke Health Care’s Wound Care business area is delighted to announce the launch of its 2025 Future Summit, an educational event bringing together healthcare professionals (HCPs) from across Europe, the Middle East, and Africa (EMEA).
-
Mölnlycke Health Care reaches 100% renewable electricity target
Mölnlycke, a world leading MedTech company, has secured 100% renewable electricity for all its established and new manufacturing sites and its headquarters, reaching its first near-term SBTi (Science Based Targets initiative)-validated target.
-
Mölnlycke Health Care announces USD 8 million investment in diabetic foot ulcer management system company Siren
-
Mölnlycke Health Care wins Swedish Sustainability Tech award
Mölnlycke is proud to announce that it has been awarded the Capgemini Swedish Sustainability Tech Award 2024 for Mölnlycke ProcedurePak® trays. This accolade recognises the company’s innovative practices and dedication to revolutionise healthcare for people and planet.